

REMARKS

Favorable reconsideration is respectfully requested in view of the foregoing amendments and the following remarks.

I. CLAIM STATUS & AMENDMENTS

Claims 1-3 and 5 were pending in this application when last examined and stand rejected.

Support for the amendment to claim 3 can be found in the disclosure, for example, at page 4, lines 9-14, page 5, line 6 and in claims 1 and 3 as filed. No new matter has been added.

Claim 2 has been canceled without prejudice or disclaimer thereto. Applicants reserve the right to file a continuation or divisional application on any cancelled subject matter.

Claim 1, 3 and 5 are pending upon entry of this amendment

II. OBVIOUSNESS REJECTION

In item 4 on pages 2-13 of the Office Action, claims 1, 3 and 5 were newly rejected under 35 U.S.C. § 103(a) as obvious over Yu et al. (Genome Res., vol. 7, no. 4, pp. 353-358, 1997) (of record as AF052135) in view of Hutchinson et al. (Nucleic Acids Research, vol. 20, no. 13, pp. 3453-3462, 1992), Solovyev et al. (Nucleic Acids Research, vol. 22, no. 24, pp. 5156-5163, 1994) and Eberhard Passarge (Color Atlas of Genetics, Georg Thieme Verlag Stuttgart, New York, Thieme Medical publishers, Inc. New York, pp. 49, 1995).

This rejection is respectfully traversed.

Amended claim 3 calls for An isolated polynucleotide encoding a human protein hAMSH having the amino acid sequence of SEQ ID No. 1, which is a signal transduction molecule for cell proliferation, wherein the polynucleotide consists of the nucleotide sequence of SEQ ID NO 2.

As acknowledged at pages 3-4 of the Office Action, Yu et al. (AF052135) only disclose a cDNA clone that contains the 1st-1356th nucleotide sequence of SEQ ID No: 2 of the instant

application. The 107th-1462nd nucleotide sequence of Yu (AF052135) is identical to the 1st-1356th nucleotide sequence of SEQ ID No: 2. The Office contends that Yu et al. (AF052135) teach a polynucleotide that is 100% identical to SEQ ID NO: 2 “over a span of” 1356 base pairs. The Office notes that the polynucleotide is “contained in” a vector, and that the polynucleotide of Yu et al. (AF052135) “contains” the polynucleotide of SEQ ID NO: 2.

Moreover, as acknowledged by the Office, Yu et al. (AF052135) does not disclose the polypeptide of SEQ ID 1, nor does it disclose which specific fragment of the polynucleotide encodes the peptide. Yu (AF052135) never discloses the coding region for a protein. The Office even acknowledges that Yu et al. (AF052135) does not disclose the start or stop coding regions of the protein. Yu et al. (AF052135) also does not disclose the functionality of the protein of the present invention.

Nonetheless, the Office argues that specific polynucleotide sequence encoding the polypeptide and the polypeptide itself would have been readily apparent to the skilled artisan based on the sequence and the knowledge in the art. The Examiner argues that it would have been obvious that three possible polypeptides can be translated “using the polynucleotide of SEQ ID NO: 2.” See the top of page 4.

However, how can the skilled artisan “use the polynucleotide of SEQ ID NO: 2”, if such sequence is not disclosed in the cited prior art. Again, as acknowledged by the Office, Yu et al. (AF052135) does not disclose or suggest a polynucleotide consisting of SEQ ID NO: 2 as claimed. Yu et al. (AF052135) only discloses a larger polynucleotide containing it. Since Yu et al. (AF052135) does not disclose SEQ ID NO: 2, it is illogical to assert that the skilled artisan could predict that three possible polypeptides can be translated “using the polynucleotide of SEQ ID NO: 2.” Instead, they would have to use the large sequence of Yu et al. containing the polynucleotide of SEQ ID NO: 2

Again, amended claim 3 is limited to a polynucleotide that consists of the nucleotide sequence of SEQ ID NO 2. Such language excludes the larger sequence in Yu et al. (AF052135) containing such sequence.

Nonetheless, the Office argues that it would have been obvious to use the polynucleotide in Yu et al. (AF052135) to determine and isolate possible DNA fragments encoding the three possible splice variants encoding the polypeptide of SEQ ID NO: 1 of the invention. See the top of page 12 of the Action. The Office asserts that the “ordinary artisan would have been motivated to identify the possible proteins encoded by the polynucleotide disclosed of Yu to determine the functionality encoded by the polynucleotide”, because “a piece of DNA is useless if it cannot be associated with a function.”

In reply, it is respectfully submitted that the mere existence of a DNA sequence is not a suggestion to investigate the sequence to identify a particular sequence contained therein that may encode a protein. To suggest otherwise is basically the same as saying that all proteins are obvious, if a larger DNA sequence exists that may encompass the specific sequence encoding the protein. Again, Yu et al. (AF052135) fail to disclose or suggest an hAMSH protein, let alone one having the amino acid sequence of SEQ ID No. 1. Moreover, Yu et al. (AF052135) does not disclose an amino acid sequence. In this regard, Yu et al. (AF052135) never discloses any protein encoded by the larger DNA sequence disclosed therein. Yu et al. (AF052135) only disclose a nucleic acid, and not a protein. Also, Yu et al. (AF052135) fail to disclose the function of the protein as a signal transduction molecule for cell proliferation. Accordingly, what motivation is there in the cited references for doing so other than the blanket assertion by the Office that “a piece of DNA is useless if it cannot be associated with a function.”

Consequently, Yu et al. (AF052135) fail to disclose or suggest the specific polynucleotide consisting of SEQ ID No: 2, encoding the hAMSH having the amino acid sequence of SEQ ID NO: 1 of the claims.

Furthermore, Yu et al. (AF052135) indicate that “All 65 cDNA clone sequences described in this paper have been submitted to the GenBank data library under accession nos. U79240-U79304.” See page 353, below the Abstract. Attached are a copy of U79240 and U79241 as an example of the submitted data. Please note that the submitted cDNA sequences are “partial” sequences. This means that the cDNAs do not encode a full length protein. More precisely, among the 65 clones, 17 clones are partial, 14 clones are complete (i.e., encoding full length protein), and the remaining 34 clones are mRNA sequences only to which partial or complete is not designated. Applicants respectfully submit that coding region for the remaining 34 clones was not determined.

Human clone 23625 is not contained in U79240-U79304, but it was submitted to GenBank under accession No. AF052135, which shows mRNA sequences only, similar to the remaining 34 clones.

Only mRNA sequences are shown for the remaining 34 clones of U79240-U79304 and AF052135. On page 4 of the Action, the Office asserts that a polypeptide can be determined from the positions of the start codon and stop codon of mRNA sequences. If this was correct, then any coding regions for the 34 clones and AF052135 might be easily determined. But Yu et al. (AF052135) did not do so. Again, please see the mRNA sequences of the attached U79240 and U79241. Even though the mRNA sequences contain some start codon (ATG), Yu et al. determined that the sequences were “partial.” In other words, contrary to the Office’s position, it would not be obvious to determine the DNA sequence encoding the polypeptide of the present invention.

As is well known in the art field, it is not easy to clone a complete cDNA fragment from mRNA molecules. The skilled artisan knows that the human clone 23625 (AF052135) was isolated by the same process as those of U79240-U79304. As such, the skilled artisan would understand that the cloning method in Yu et al. is inadequate for cloning “complete cDNA.”

For these reasons, it is clear that Yu et al. (AF052135) fail to disclose or suggest the specific polynucleotide consisting of SEQ ID No: 2, encoding the hAMSH having the amino acid sequence of SEQ ID NO: 1 of the claims. Moreover, it would not have been obvious to identify the coding region of the DNA and then obtain the hAMSH having the amino acid sequence of SEQ ID NO: 1.

In view of the above, the above-noted 103(a) obviousness rejection is untenable and should be withdrawn.

III. ANTICIPATION REJECTION

In item 5 on pages 14-24 of the Action, claims 1, 3 and 5 were newly rejected under 35 U.S.C. 102(a) as being anticipated by Tanaka et al. (J. Biol. Chem., vol. 274, no. 27, pp. 19129-19135, July 2, 1999 and GenEmbl sequence Accession U73522 of the clone contained therein). The Office has asserted that Tanaka et al. (U73522) discloses the polynucleotide AMSH of SEQ ID NO: 2 of the present invention.

This rejection is respectfully traversed on the basis that Tanaka et al. (U73522) is not available as prior art against the present invention.

The instant application is a 371 of PCT/JP99/06309, filed November 12, 1999, which claims foreign priority to Japanese patent application No. 1998-322674, filed November 12, 1998. Kindly note that the Office has previously acknowledged the foreign priority claim and receipt of certified copies of the foreign priority document. See item 12(a)1 on page 1 of the Office Action of December 10, 2003.

Thus, Applicants' November 12, 1998 priority date precedes the July 2, 1999 publication date of Tanaka et al. (U73522). Therefore, Tanaka et al. (U73522) is not available as prior art against the present invention. For this reason, the rejection is improper and should be withdrawn.

IV. WRITTEN DESCRIPTION REJECTIONS

In item 7 on pages 24-27 of the Action, claims 2 was newly rejected under 35 U.S.C. § 112, first paragraph, as failing to comply with the written description requirement.

For the sole purpose of expediting prosecution and without intending to acquiesce to the rejection, the present amendment cancels claim 2, thereby obviating this rejection.

In items 8-9 on pages 27-28, claim 3 was newly rejected under 35 U.S.C. § 112, first paragraph, as failing to comply with the written description requirement. This is a new matter rejection. The amendment filed December 7, 2005 is also objected to for adding new matter. The Office has argued that the species of the polynucleotide which consists of the nucleotide sequence from the 11th to the 1285th nucleotide of SEQ ID No.2 constitutes new matter.

For the sole purpose of expediting prosecution and without intending to acquiesce to this rejection, the objected language has been removed from claim 3. Thus, the present amendment overcomes this rejection.

V. PATENTABLE SUBJECT MATTER

In item 10 on pages 28-29 of the Action, claim 3 was newly rejected under 35 U.S.C. 101 on the basis that the claimed invention is directed to non-statutory subject matter for lacking language indicating the polynucleotide is isolated or purified from nature.

The present amendment overcomes this rejection by amending the claim to recite an “isolated” before “polynucleotide” as suggested by the Office. As such, the amended claim no longer reads on a product of nature.

VI CONCLUSION

In view of the foregoing amendments and remarks, it is respectfully submitted that the present application is in condition for allowance and early notice to that effect is hereby requested.

Attorney Docket No. 2001_0572A
Serial No. 09/831,452
August 31, 2007

If the Examiner has any comments or proposals for expediting prosecution, please contact the undersigned attorney at the telephone number below.

Respectfully submitted,

Kazuo SUGAMURA et al.

By: _____


Jay F. Williams

Registration No. 48,036


Attorney for Applicant

JFW
Washington, D.C. 20006-1021
Telephone (202) 721-8200
Facsimile (202) 721-8250
August 31, 2007

Attorney Docket No. 2001_0572A
Serial No. 09/831,452
August 31, 2007

ATTACHMENTS:

1. Copy of U79240, U79241, and AF0523135 submitted in Yu et al. .



My NCBI

[Sign In] [Register]

Search Nucleotide

for

Go

Clear

Limits

Preview/Index

History

Clipboard

Details

Display GenBank

Show 5

Send to

Hide:

☐ sequence☐ all but gene, CDS and mRNA features

Range: from begin

to end

☐ Reverse complemented strand

Features:

☐ SNP

Refresh

1: U79240. Repons Human serine/thre...[gi:1710185]

Links

Features Sequence

LOCUS HSU79240 1876 bp mRNA linear PRI 25-MAR-1997

DEFINITION Human serine/threonine kinase mRNA, partial cds.

ACCESSION U79240

VERSION U79240.1 GI:1710185

KEYWORDS

SOURCE Homo sapiens (human)

ORGANISM Homo sapiens

Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.

REFERENCE 1 (bases 1 to 1876)

AUTHORS Andersson, B., Wentland, M.A., Ricafrente, J.Y., Liu, W. and Gibbs, R.A.

TITLE A 'double adaptor' method for improved shotgun library construction

JOURNAL Anal. Biochem. 236 (1), 107-113 (1996)

MEDLINE 96207227

REFERENCE 2 (bases 1 to 1876)

AUTHORS Yu, W., Andersson, B., Worley, K.C., Muzny, D.M., Ding, Y., Liu, W., Ricafrente, J.Y., Wentland, M.A., Lennon, G. and Gibbs, R.A.

TITLE Large Scale Concatenation cDNA Sequencing

JOURNAL Unpublished

REFERENCE 3 (bases 1 to 1876)

AUTHORS Yu, W. and Gibbs, R.A.

TITLE Direct Submission

JOURNAL Submitted (22-NOV-1996) Molecular and Human Genetics, Baylor College of Medicine, One Baylor Plaza S930, Houston, TX 77030, USA

FEATURES

source Location/Qualifiers

1..1876

/organism="Homo sapiens"

/mol_type="mRNA"

/db_xref="taxon:9606"

/clone="23545"

/sex="female"

/tissue_type="brain"

/clone_lib="Soares library 1NIB from IMAGE consortium"

/dev_stage="infant"

1..1379

/note="similar to M. musculus serine/threonine protein kinase encoded by GenBank Accession Number X70764"

/codon_start=3

/product="serine/threonine protein kinase"

/protein_id="AAB50198.1"

/db_xref="GI:1710185"

/translation="RLNQVQTSTPVIWMRGAAGLQREIQEGAYSGSCYHRDGLRLSIQ
FVYRRVELQGTPLFCCWLVKDLLHSQRDQAARTRFLASLPGSTHSTAELTGPSLV
EVLRARPFWEPPKAVELEGLAACGEYSQKYSTHSPGSGAFGFVWTAVDKEKNKEV
VVKFIKKEKVLDCWIEDPKLGKVTLEIAILSRVEHANIIVLDIFENQGFQLVMEK
HSGGLDLFAFIDRHPRLDPLASYIFRQLVSAVGYLRLKDIHRDFKDNIVIAEDFT
IKLIDPGSAAYLERGKLFYTFCGTIEYCAPEVLMGNPYPYRGPPELMWSLGVTLVTFE
ENPFCELEBTVEAAIHPPYLVSKELMSLVSGLLQPVPFERRTTLEKLVTDPMVTPVNL
ADYTWEEFVRVKNKPESGVLAAASLEMGNRSLSDVAQAQELCGGPVPGAPNGQGCLHP
GDPRLLLTS"

CDS

ORIGIN

```

1 caaggctgaa cgtccaggtc acctccacgc ccgtgatcgt gatgcgcggg gctgctggcc
61 tgcagcggga gatccaggag ggtgcctact ccgggagctg ctaccatcga gatggcttac
121 ggctgagtat acagtttgag gtgaggcggg tggagctcca gggcccccaca cctctgtctc
181 gctgctggcc ggtgaaagac ctctccaca gccaaacgca ctacagccgc aggaacccgc
241 cgtccctcgc cagcctgcc ggctccacc actctaccgc tgcctgagctc accggaccga
301 gcccggtgga agtgctcaga gccagaccct ggcttgagga gcccccaca gctgtggaac

```

361 tggagggtt ggccgctgt gagggcgagt actcccaaaa gtacagtacc atgagcccg
421 tgggagtg ggccttcggc tccgtgtgga ctcctgtgga caaggaaaaa aacaaggagg
481 tgggtgtgaa gtttatcaag aaggagaagg tcttgaggga ttgttggtt gaggatccca
541 aacttgggaa agtactcta gagaccgcaa ttctatccag ggtggagcac gccaatatca
601 tcaaggatc ggatatattt gaaaaccaag ggtcttcca gcttggtgatg gagaagcacg
661 gctccggcct agacctcttc gcttctcatc accgccacc caggctggat gagcccttg
721 cgagctacat ctcccgacaa ctagtgtcag cagtgggata cctgcgcttg aaggacatca
781 tccaccgtga cttcaaggac gagaacaccg cgatcgccga ggacttcaca atcaagctga
841 tagaacttgg ctccggcgc taccgtgaaa ggggaaaaat attttatact ttttgtggga
901 ccacgagca ctgtgcaccg gaagtcttca tggggaatcc ctacagaggg cgggagctgg
961 agatgtggtc tctggggagt actctgtaca cgtcgtctt tgaggagAAC cccttctgtg
1021 agctggaggga gaccgtggag gctgocatac acccgccata cctgggtgtcc aaagaactca
1081 tgagccttgt gtctgggctg ctgcagccag tccctgagag acgcaccacc ttggagaagc
1141 tgggtgacaga cccgtgggta acacagcctg tgaatcttgc tgaatataca tgggaagagg
1201 tgttctgagt aaacaagcca gaaagtggag ttctgtccgc tgcgagcctg gagatgggga
1261 acaggagcct gagtgtatgt gccaggtctc agtagcttct tgggggcccc gttccaggcg
1321 aggtctccaa tggccaaggc tgtttgcac cgggggatcc ccgtctgtctg accagctaaa
1381 caccaatttc tctctgctt tctccacttg gtttggaaaa tcacacagtt ttcaggctcc
1441 atcctgttgg agaaaaatca tctcgaagca tccccaattc accttctaaa aactcatgtg
1501 caggcttcat aaacaccaga acagaagaca gtgatgtgt attatttttag atttattaca
1561 tagatttggg attcacttct tctcatgacct agaaaaaaac attccagtgt tcaactgttt
1621 tatattatta aagggtcttt aatttgtgaa cttctgaagg catgagtgtt tctcttttct
1681 acttttgtat atgtgcatgt tttgttctct ctgacttggc atatgtctat ctgagtgcg
1741 gatcatgtga atttctgaga ctggttagtc aaatggccag actatttcat taattttatt
1801 cctcaaatgc ttttcaaatt aaagcacctt tgttagtaaa cagttaaaaa aaaaaaaaaa
1861 aaaaaaaaaa aaaaaa

//

Disclaimer | Write to the Help Desk
NCBI | NLM | NIH

for 13/2007 13:54:08



Nucleotide

My NCBI

[Sign In] [Register]

Search Nucleotide

for

Go

Clear

Limits

Preview/Index

History

Clipboard

Details

Display GenBank

Show 5

Send to

Hide: ☐sequence ☐

all but gene. CDS and mRNA features

Range: from begin

to end

☐ Reverse complemented strandFeatures: ☐

Refresh

1: U79241. Reports Human clone 23759...[gi:1710187]

Links

Features Sequence


LOCUS HSU79241 1410 bp mRNA linear PRI 25-MAR-1997
DEFINITION Human clone 23759 mRNA, partial cds.
ACCESSION U79241
VERSION U79241.1 GI:1710187
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1 (bases 1 to 1410)
AUTHORS Andersson, B., Wentland, M.A., Ricafrente, J.Y., Liu, W. and Gibbs, R.A.
TITLE A 'double adaptor' method for improved shotgun library construction
JOURNAL Anal. Biochem. 236 (1), 107-113 (1996)
MEDLINE 96207227
REFERENCE 2 (bases 1 to 1410)
AUTHORS Yu, W., Andersson, B., Worley, K.C., Muzny, D.M., Ding, Y., Liu, W.,
Ricafrente, J.Y., Wentland, M.A., Lennon, G. and Gibbs, R.A.
TITLE Large Scale Concatenation cDNA Sequencing
JOURNAL Unpublished
REFERENCE 3 (bases 1 to 1410)
AUTHORS Yu, W. and Gibbs, R.A.
TITLE Direct Submission
JOURNAL Submitted (22-NOV-1996) Molecular and Human Genetics, Baylor
College of Medicine, One Baylor Plaza S930, Houston, TX 77030, USA
FEATURES
source Location/Qualifiers
1..1410
/organism="Homo sapiens"
/mol_type="mRNA"
/db_xref="taxon:9606"
/clone="23759"
/sex="female"
/tissue_type="brain"
/clone_lib="Soares library 1NIB from IMAGE consortium"
/dev_stage="infant"
CDS
1..1316
/codon_start=3
/product="unknown"
/protein_id="AAB50189.1"
/db_xref="GI:1710188"
/translation="VVPDEVATIAAEVTSFSNRFTHTVLTAGGIGPTHDDVTFEAVAQA
FGDELKPHPKLEAATKALGGEGWEKLSLPSSARLHYGTDPTGQPPFRFPLVSVRVY
LFFGIPELLRRVLGEMKGLFQNPVQFHSKELYVAADAEASIPILAEQAHFGRRLGL
GSYPDWGSNYQVKLTLDSEEEGPLLECLAYLTARLPQGSVPYMPNAVEQASEAVYK
LAESGSSLGKKVAGALQTIETSLAQYSLTQLCVGFNGGKDCTALLHLFHAAVQRKLDP
VENPLQILYIRSISPPFPELEQFLQDTIKRYNLQMLEAEGSMKQALGELQARHPQLEAV
LMGTRRTDPYSCSLCFPSPTDPCWPAFMRINPLLDWTYRDIWDFLRQLFVPCILYDR
GYTSLGSRNTVRNPALKCLSPGGHPTYRPAYLENEEEERNST"
ORIGIN
1 cagtctgacc tgatgaggta gccaccattg cagctgaggt cacttctttc tccaaccgct
61 tcacccatgt cctcacagca gggggcatcg gcccactca tgatgatgtg acctttgagg
121 cagtggcaca ggccttttga gatgagatga agccacaccc caagtctggaa gcagccacca
181 aagcctctag aggggaagga tgggagaagc tatcatctgt gccctctctt gcccgcttgc
241 attatggcac agatccttgc actggtaaac ctttcagatt ccctcttggt tccgtctgaa
301 acgtctaccc cttcccagtc attccagagc tgctgcggcg ggtgctggag gggatgaagg
361 gactattcca aaacccagct gtccagttcc actcaaagga gctatatgtg gctgctgatg
421 aagcctccat cgccccatt ctggctgagg cccaggccca cttgggacgt aggcttgccc
481 tgggttccca ccttgacttg ggcagcaact actatcaggt gaagctgact ctgactcag

541 aggaagaagg acccctggag gaatgcttgg cctacctgac tgcctgtttg cccagggat
601 cgttgggtccc ctacatgccc aacgtgttgg agcaggccag tgaggctgta tacaacctcg
661 ctgaatcagg gtcttcttctg gggaaaaagg tggcagggtgc cctacagacc attgagacct
721 ccctgggtcca gtacagcctc acccagctct gtgtgggtct caacgggggc aaagactgca
781 ctgcccctcct gacccctcttc catgcagctg tgcagaggaa attacctgat gtcccaaac
841 cctccagat. cctgtatata cgcagcatct ccccttccc tgagctggaa cagtttctac
901 aggacactat caagaggat aacctgcaga tgttgggaagc tgagggcagc atgaagcagg
961 cccctgggtga actgcaggca cggcaccccc agctggaggc tgtccttatg ggcaccgccc
1021 ggactgacct ctactcttgt agcctctgac ctttcagccc cactgaccca ggctggcccg
1081 cattcatgag catcaaccca ctgctggact ggacctacag agacatctgg gattttctgc
1141 gtcagctgtt tgtcccatac tgtatcctgt atgacctgagg atacacatca ctggggagtc
1201 gggagaatac cgtgcggaac ccggccctga agtgccctgag cccaggagga caccocacat
1261 accgtccagc ctatctactg gagaatgahg aagaggagcg gaactccgc acatgacctc
1321 ccaccttagg agggaggga ggacaocgct ctagggtata acctggcaat aaacctgtgc
1381 tctcactgtg aaaaaaaaaa aaaaaaaaaa

//

Disclaimer | Write to the Help Desk
NCBI | NLM | NIH

Jun 10 2007 13:56:00



My NCBI

[Sign In] [Register]

Nucleotide

Protein

Gene

Structure

Pathway

Taxonomy

Map

Biology

Books

Search CoreNucleotide for

Go

Clear

Limits

Preview/Index

History

Clipboard

Details

Display GenBank

Show 5

Send to

Hide: ☐sequence ☐

all but gene, CDS and mRNA features

Range: from begin

to end

☐ Reverse complemented strandFeatures: ☐

Refresh

1: AF052135. Reports Homo sapiens clone...[gi:3360444]

Links

Features Sequence

LOCUS AF052135 1462 bp mRNA linear PRI 05-AUG-1998

DEFINITION Homo sapiens clone 23625 mRNA sequence.

ACCESSION AF052135

VERSION AF052135.1 GI:3360444

KEYWORDS FLI_CDNA.

SOURCE Homo sapiens (human)

ORGANISM Homo sapiens

Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; Homo.

REFERENCE 1 (bases 1 to 1462)

AUTHORS Andersson, B., Wentland, M.A., Ricafrente, J.Y., Liu, W. and Gibbs, R.A.

TITLE A 'double adaptor' method for improved shotgun library construction

JOURNAL Anal. Biochem. 236 (1), 107-113 (1996)

PUBMED 2619474

REFERENCE 2 (bases 1 to 1462)

AUTHORS Yu, W., Andersson, B., Worley, K.C., Muzny, D.M., Ding, Y., Liu, W., Ricafrente, J.Y., Wentland, M.A., Lennon, G. and Gibbs, R.A.

TITLE Large-scale concatenation cDNA sequencing

JOURNAL Genome Res. 7 (4), 353-358 (1997)

PUBMED 9110174

REFERENCE 3 (bases 1 to 1462)

AUTHORS Yu, W., Sarginson, J. and Gibbs, R.A.

TITLE Direct Submission

JOURNAL Submitted (05-MAR-1998) Molecular and Human Genetics, Baylor College of Medicine, One Baylor Plaza S930, Houston, TX 77030, USA

FEATURES

source Location/Qualifiers

1..1462

/organism="Homo sapiens"

/mol_type="mRNA"

/db_xref="taxon:9606"

/clone="I.M.A.G.E. Consortium clone ID 23625"

/sex="female"

/tissue_type="brain"

/clone_lib="INIB"

/dev_stage="infant"

ORIGIN

```

1  gctgcattccc ctttttggaa ttgctcaacc aggtggtaac cggcgccgct tectggcctt
61  gggagggtggt tcctttctta acccacaaga acctctccca agagaacttg gtctgatgt
121  ctgaccatgg agatgtgagc ctcccggccg aagaccgggt gagggtcttc tcccagctgg
181  gtatgtcggt agaggtgaat gaagacattc caccctcgct gtacttccgc tctggagtgt
241  agattatccg aatggcattc atttactctg aggaaggcaa cattgaacat gccttcattc
301  tctataacaa gtatatcacc ctctttattg agaaactacc aaaacatcga gattacaaat
361  ctgctgtcat tctgaaaaag aaagacacag taaagaaatt aaaggagatt gcatttccca
421  aagcagaaga cctgaaggca gagctgttaa aacgatatac caaagaatat acagaatata
481  atgaagaaaa gaagaaggaa gcagaggaaat tggcccgtaa catggccatc cagcaagagc
541  tggaaaagga aaaacagagg gtacacacac agaagcagca gcaattggaa caggaaacgt
601  tccatgcctt caggagatg atccggaaac aggagctaga aaaagagcga ctgaaaactg
661  tacaggagtc cgggaaggta gacctggccc taggtggccc gctagtgcct gacttgga
721  agccctctct agatgtgttc cccaccttaa cagtctcatc catacagcct tcagactgtc
781  acacaactgt aaggccagct aagccacctg tggtagacag gacctgaaa cctggagcac
841  tgagcaactc agaaagtatt cccacaatcg atggattgct ccatgtgtgt gtgcttgggc
901  ggtgtgtccc acagttcttc cagttagcca gtgccaacac tgcccgggga gtggagacat
961  gtggaattct ctgtggaaaa ctgatggagg atgaatttac cattaccatc gttctcatcc
1021  ccaagcaaa gctgtgggtct gattactgca acacagagaa cgaagaagaa ctttctctca
1081  tacaggatca gcagggcctc atcacactgg gctggattca tactacccc acacagaccg
1141  cgtttctctc cagtgtcgac ctacacactc actgctctta ccagatgatg ttgccagagt

```

```
1201 cagtagccat tgtttgctcc cccaagttcc aggaactgg attctttaa ctaactgacc
1261 atggactaga ggagatttct tcctgtcgcc agaaaggatt tcatccacac agcaaggatc
1321 caccctctgt ctgtagctgc agccacgtga ctgttctgga cagagcagtg accatcacag
1381 accctcgatg agcgtttgag tccaacacct tccaagaaca acaaaacctat atcagtgtac
1441 tgtagccccc taatttaagc tt
```

//

Disclaimer | Write to the Help Desk
NCBI | NLM | NIH

Jun 19 2007 11:00